Document:

<Page>

                                                                    EXHIBIT 10.1

                      THIRD AMENDMENT TO LICENSE AGREEMENT

     This Amendment to License Agreement ("Amendment") is entered into as of
August 26, 2002, by and between BUKWANG PHARM. CO., LTD., with its principal
offices at 398-01, Daebang-Dong, Dongjak-Ku, Seoul 156-811, Korea ("Bukwang")
and TRIANGLE PHARMACEUTICALS, INC., with its principal offices located at 4
University Place, 4611 University Drive, Durham, North Carolina 27707
("Triangle") and amends certain terms of that certain License Agreement, dated
as of February 27, 1998, between Bukwang and Triangle, as amended April 1, 1999
and September 5, 2000 (the "Agreement"). Capitalized terms not defined herein
shall have the meanings given them in the Agreement.

                                    RECITALS

     A.   Bukwang and Triangle have previously entered into the Agreement,
pursuant to which Bukwang has licensed certain patent rights and know-how to
Triangle relating to a compound known as L-FMAU (also known as clevudine).

     B.   Triangle has certain diligence obligations with respect to the
clinical development of a Licensed Product.

     C.   Bukwang and Triangle desire to amend and clarify certain terms of the
Agreement relating to milestone payments and diligence obligations and the
calculation of Net Sales.

     NOW, THEREFORE, for good and valuable consideration, Triangle and Bukwang
hereby agree as follows:

<Page>

          1.   AMENDMENTS. The Agreement is hereby amended as follows:

          (a)  Section 1.23. Delete Section 1.22 and replace it with the
     following:

               "NDA" shall mean a New Drug Application or its equivalent filed
          in the U.S., China, Japan, Taiwan or, in the case of Europe, with the
          European Agency for the Evaluation of Medicinal Products."

          (b)  SECTION 1.24. Delete Section 1.24 and replace it with the
     following:

               "'Net Sales' of Licensed Products which contain as their active
          ingredients one or more Compounds and other compounds (a 'Combination
          Product') shall mean the portion of the gross sales price of such
          Combination Product attributable to the Compounds contained therein,
          billed by Triangle, its Affiliates or sublicensees to independent
          customers, including any consideration received, directly or
          indirectly, from such customers in respect of the sale, distribution
          or transfer of Licensed Products, less all the allowances,
          adjustments, reductions, discounts, taxes, duties, rebates and other
          items referred to in Section 1.23. The "portion of the gross sales
          price of such Combination Product attributable to the Compounds
          contained therein" shall be determined on a country-by-country basis
          and shall mean, in each country, the average gross sales price per
          gram of a Compound in the most comparable stock keeping unit of a
          Licensed Product having a Compound as the sole active ingredient in
          that country multiplied by the total number of grams of Compound
          contained in the Combination Product billed in that country during
          such royalty period.

               In the event that a Combination Product containing a Compound and
          one other active ingredient is sold in a country before a Licensed
          Product containing only one or more Compounds is sold in that country,
          the portion of gross sales price of such Combination Product
          attributable to Compounds until a Licensed Product containing only one
          or more Compounds as active ingredients is sold in that country shall
          be *** percent. In the event that a Combination Product containing a
          Compound and two or more other compounds as active ingredients is sold
          in a country before a Licensed Product containing only one or more
          Compounds is sold in that country, the portion of gross sales price of
          such Combination products attributable to Compounds until a Licensed
          Product containing only one or more Compounds as active ingredients is
          sold in that country shall be the percentage determined by ***.

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

                                        2
<Page>

               In the event that Triangle or its Affiliates or sublicensees
          distribute any Licensed Products to a third party for non-monetary
          consideration (e.g. barter or exchange), such distribution shall be
          considered a sale for accounting and royalty purposes. Net Sales for
          any such distributions shall be determined on a country-by-country
          basis and shall be the average price of 'arm's length' sales by
          Triangle or its Affiliates or sublicensees in such country in the
          Territory during the royalty period in which such sale occurs or, if
          no such 'arm's length' sales occurred in such country in the Territory
          during such royalty period, during the last royalty period in which
          such 'arm's length' sales occurred. If no 'arm's length' sales have
          occurred in a particular country in the Territory, Net Sales for any
          such distributions in such country in the Territory, shall be the
          average price of 'arm's length' sales in all countries in the
          Territory during such royalty period."

          (c)  SECTION 1.25. Delete Section 1.25 and replace it with the
     following:

               "'Phase II Completion Date' shall mean sixty (60) days after the
          completion of statistical analyses of the final results of those Phase
          II clinical trials which Triangle considers reasonably necessary for
          purposes of inclusion in an NDA for approval of a Licensed Product for
          HBV. As used in the preceding sentence, 'Phase II clinical trials'
          shall mean those well-controlled clinical trials sponsored by Triangle
          or Bukwang, the primary objective of which is to ascertain additional
          data regarding the safety and tolerance of a Licensed Product and
          preliminary data regarding such Licensed Product's antiviral effects
          against HBV."

          (d)  SECTION 1.26. Delete Section 1.26 and replace it with the
     following:

               "'Phase III Completion Date' shall mean sixty (60) days after the
          completion of statistical analyses of the final results of those
          Phase  III  clinical  trials  which  Triangle   considers   reasonably
          necessary  for  purposes  of  inclusion  in an NDA for  approval  of a
          Licensed  Product for HBV. As used in the preceding  sentence,
          'Phase III clinical trials' shall mean those well-controlled  clinical
          trials  sponsored  by Triangle or Bukwang,  the primary  objective  of
          which  is to  ascertain  definitive  safety  data  and  efficacy  data
          regarding  such  Licensed  Product's  antiviral  effects  against  HBV
          sufficient to support an NDA.

          (e)  SECTION 3.2.

               (i)  Delete Section 3.2(a)(vi) and replace it with the following:

                                        3
<Page>

               "(vi) ***

               (ii) Add the following after the Milestone and Milestone Payment
          chart in Section 3.2(a):

               "(1) If the Milestone Payment identified in item (iii) above has
               not been paid by *** and Triangle has not given notice of
               termination of this Agreement prior to such date, Triangle will
               pay Bukwang *** , such amount to be credited against the
               Milestone Payment due on ***.

               (2)  The balance *** of the Milestone Payment due on *** shall be
                    paid to Bukwang upon the first to occur of *** or *** .

               (3)  If the Milestone Payment identified in item (iv) above has
               not been paid by *** and Triangle has not given notice of
               termination of this Agreement prior to such date, Triangle will
               pay Bukwang *** , such amount to be credited against the
               Milestone Payment due on *** .

               (4)  The balance *** of the Milestone Payment due on ***shall be
                    paid to Bukwang upon the first to occur of *** or ***."

          (f)  SUBSECTIONS 6.2(a)(i) AND 6.2(a)(ii). Delete Subsections
     6.2(a)(i) and 6.2(a)(ii) and replace them as follows:

                    "(i) files what it reasonably believes to be a complete NDA
               for a Licensed Product for HBV within *** after the Effective
               Date; provided, however, said *** period shall be subject to up
               to *** extensions of *** each, at Triangle's election, by payment
               to Bukwang of a sum of *** for each *** extensions, *** for each
               *** extensions and *** for each *** extensions; and"

                    "(ii) "files an NDA for a Licensed Product containing the
               Compound as its sole active ingredient no later than the same
               time as Triangle files an NDA for a Combination Product; and"

          (f)  SUBSECTION 6.2(a)(iii). A new Subsection 6.2(a)(iii) shall be
               inserted as follows:

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

                                        4
<Page>

                    "(iii) commercially introduces, or causes its Affiliates or
               sublicensees to commercially introduce, any Licensed Product
               (including any Licensed Product containing the Compound as its
               sole active ingredient) approved in any country in which an NDA
               has been filed within *** of Registration of such Licensed
               Product in such country."

          (g)  SECTION 7.3. Delete the word "and" at the end of Subsection
     7.3(b). Delete the period at the end of Subsection 7.3(c) and insert ";
     and" and add the following Subsection 7.3(d):

               "(d) evaluating all preclinical and clinical data in order to
               assess the optimal dose of Licensed Products containing the
               Compound as its sole active ingredient or containing the Compound
               as one active ingredient in Combination Product to be used in
               Phase III clinical studies to support Registration of Licensed
               Products."

     2.   GENERAL TERMS. The Agreement, as amended by this Amendment,
constitutes the entire agreement between Bukwang and Triangle or regarding the
subject matters contained therein and herein. In the event of any conflict
between the provisions of the Agreement and this Amendment, the provisions of
this Amendment shall govern and control. This Amendment shall be governed by,
and construed in accordance with, the laws of the State of Georgia without
regard to its conflicts of laws principles. This Amendment may be executed in
any number of counterparts, each of which shall be deemed an original and all of
which shall constitute one and the same instrument. If any provision of this
Amendment is for any reason held to be ineffective, unenforceable or illegal,
such condition shall not affect the validity or enforceability of any of the
remaining portions hereof; provided, further, that the parties shall negotiate
in good faith to replace any ineffective, unenforceable or illegal provision
with an effective replacement as soon as is practical.

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

                                        5
<Page>

     IN WITNESS WHEREOF, Bukwang and Triangle have each executed this Amendment
through an authorized officer as of the date written below.

                                         BUKWANG PHARM. CO., LTD.

                                         By:    /s/ S.K. Lee
                                                ------------------------------
                                         Its:   Executive Managing Director
                                                ------------------------------
                                         Date:  August 27, 2002
                                                ------------------------------

                                         TRIANGLE PHARMACEUTICALS, INC.

                                         By:    /s/ R. Andrew Finkle
                                                ------------------------------
                                         Its:   Executive Vice President
                                                ------------------------------
                                         Date:  August 26, 2002
                                                ------------------------------

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

                                        6<Page>

                                                                    EXHIBIT 10.2

                              TERMINATION AGREEMENT

     This Termination Agreement is dated as of this 30th day of July, 2002, by
and between Abbott Laboratories, an Illinois corporation with its principal
place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064
("Abbott") and Triangle Pharmaceuticals, Inc., a Delaware corporation with its
principal place of business at 4 University Place, 4611 University Drive,
Durham, North Carolina 27707 ("Triangle").

                                   WITNESSETH

     WHEREAS, Abbott and Triangle previously entered into a business
collaboration comprised of the following legal agreements:

          (i)   Collaboration Agreement dated as of June 2, 1999, and amended by
                the First Amendment to Collaboration Agreement dated as of the
                15th day of October, 1999 (the "Collaboration Agreement"),
                whereby Abbott and Triangle agreed to collaborate with respect
                to the clinical development, registration, distribution and
                marketing of Triangle's proprietary drugs for the treatment of
                HIV, HBV and other indications;

          (ii)  Common Stock Purchase Agreement dated as of June 2, 1999 (the
                "Stock Purchase Agreement") whereby Triangle sold to Abbott
                6,571,428 shares of Triangle's common stock;

          (iii) Triangle Pharmaceuticals, Inc. Stockholder Rights Agreement
                dated as of June 2, 1999 (the "Stockholder Rights Agreement")
                which provided Abbott and Triangle certain rights related to the
                Triangle common stock purchased by Abbott;

          (iv)  Supply and  Manufacturing  Agreement  dated as of August 3, 1999
                (the "Prior  Manufacturing  Agreement") whereby Abbott agreed to
                supply  Triangle's  uncommitted  requirements  of bulk  drug for
                Triangle's   various    proprietary   drugs   covered   by   the
                Collaboration Agreement; and

          (v)   Co-Promotion Agreement dated as of June 2, 1999, as amended by a
                letter agreement dated February 12, 2001 (the "Co-Promotion
                Agreement") whereby Abbott granted Triangle the right to
                co-promote Abbott's protease inhibitors Norvir and Kaletra.

     WHEREAS, the parties desire to terminate their collaboration and to
terminate the Collaboration Agreement, the Stock Purchase Agreement, the Prior
Manufacturing Agreement, and the Co-Promotion Agreement and amend the
Stockholder Rights Agreement; and

<Page>

                                      - 2 -

     WHEREAS, to close out and restructure their business relationship the
parties desire to enter into this Termination Agreement, an amendment to the
Stockholder Rights Agreement (the "First Amendment to Stockholder Rights
Agreement"), a new Supply and Manufacturing Agreement (the "Manufacturing
Agreement"), and a Credit Line Agreement (the "Credit Agreement"), all of even
date herewith.

     NOW, THEREFORE, in consideration of the foregoing and the mutual covenants
and undertakings contained herein, the parties agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

     In addition to the other terms defined elsewhere herein, the following
terms shall have the following meanings when used in this Agreement (and any
term defined in the singular shall have the same meaning when used in the
plural, and vice versa, unless stated otherwise):

     1.1  "Abbott Patents" shall mean (a) any patents or patent applications
owned by or otherwise licensed to or controlled by Abbott (to the extent
sublicensing is permissible) as of the Effective Date or arising on or after the
Effective Date under the Manufacturing Agreement, which include claims covering
or potentially covering the manufacture, use or sale of the Compounds or
Products; and (b) all substitutions, extensions, divisionals, continuations,
continuations-in-part, reissues, reexaminations, renewals, supplementary
protection certificates or foreign counterparts of such patents and patent
applications identified in sub-part (a).

     1.2  "Abbott Technology" shall mean all technical information, inventions,
discoveries, trade secrets, information, experience, data, formulas, procedures,
processes, know-know and results which are necessary for the development,
registration, manufacture, use or sale of the Compounds or Products and which
are owned by or otherwise licensed to or controlled by Abbott (to the extent
sublicensing is permissible) as of the Effective Date or arising on or after the
Effective Date under the Manufacturing Agreement.

     1.3  "Affiliate" shall mean any corporation or non-corporate business
entity which controls, is controlled by, or is under common control with a
party. A corporation or non-corporate business entity shall be regarded as in
control of another corporation or non-corporate business entity if it owns, or
directly or indirectly controls, at least *** percent (***%) of the voting stock
of the other corporation, or (a) in the absence of the ownership of at least ***
percent (***%) of the voting stock of a corporation or (b) in the case of a
non-corporate business entity, if it possesses, directly or indirectly, the
power to direct or cause the direction of the management and policies of such
corporation or non-corporate business entity, as applicable. For purposes of
this Agreement, TAP Holdings Inc. and its

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                      - 3 -

subsidiaries ("TAP"), which comprise Abbott's joint venture with Takeda Chemical
Industries Ltd., are not Affiliates of Abbott.

     1.4  "Co-Promotion Agreement" shall have the meaning set forth in the first
"Whereas Clause."

     1.5  "Collaboration Agreement" shall have the meaning set forth in the
first "Whereas Clause."

     1.6  "Combination Product" shall have the meaning given in Section 1.14.

     1.7  "Compounds" shall mean MKC-442, FTC, L-FMAU, and DAPD.

     1.8  "DAPD" shall mean (i) (beta)-D-Dioxolanyl purines of the formula set
forth on Exhibit 1.8 to this Agreement wherein R is OH, Cl, NH(2), or H, and X
is H, alkyl, acyl, monophosphate, diphosphate or triphosphate; (ii) all 5' and
N(6) acylated and alkylated derivatives thereof; (iii) any salts, esters,
racemic mixtures and purified enantiomers of any of the foregoing; and (iv) any
and all polymorphs, hydratets and solvates of any of the foregoing. DAPD is
exclusively licensed to Triangle by Emory University and the University of
Georgia Research Foundation, Inc., pursuant to a License Agreement dated March
31, 1996, as amended July 10, 2000 (the "DAPD License Agreement") for use as a
pharmaceutical product in the prevention and treatment of HIV and HBV throughout
the entire world. Abbott's rights and obligations under the DAPD License
Agreement will terminate as a result of termination of the Collaboration
Agreement pursuant to Section 2.1 of this Agreement.

     1.9  "Effective Date" shall mean the date set forth in the introductory
paragraph of this Agreement.

     1.10 "FTC" shall mean (i) the (-) enantiomer with the chemical name
(2R-cis)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)
-pyrimidinone; (ii) any mixture of the (-) enantiomer described in Subsection
1.10(i) and the (+) enantiomer with the chemical name (2S-cis)-4-amino-5-
fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H) -pyrimidinone, *** ;
(iii) any salts, esters (including, but not limited to, all 5' phosphate esters)
and N alkylated derivatives of any of the foregoing; or (iv) any and all
polymorphs, hydrates and solvates of any of the foregoing. FTC is exclusively
licensed to Triangle by Emory University pursuant to a License Agreement dated
April 17, 1996, as amended on May 6, 1999 and on July 10, 2000 (the "FTC License
Agreement") for use in the prevention and treatment of HIV and HBV throughout
the entire world. Abbott's rights and obligations under the FTC License
Agreement will terminate as a result of termination of the Collaboration
Agreement pursuant to Section 2.1 of this Agreement.

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                      - 4 -

     1.11 "Field of Use" shall mean the following: (i) for MKC-442, all
pharmaceutical uses; (ii) for FTC and DAPD, the prevention and treatment of HIV
and HBV; (iii) for L-FMAU, all human antiviral applications and uses; and (iv)
any other uses for the Compounds to which Triangle obtains rights from the
Triangle Licensors.

     1.12 "HBV" shall mean the hepatitis B virus.

     1.13 "HIV" shall mean the human immunodeficiency virus.

     1.14 "L-FMAU" shall mean the compound known as L-FMAU, with the chemical
name 2'-flouro-5-methyl-(beta)-L-arabinofuranosyluracil, including any salts and
esters thereof. L-FMAU is exclusively licensed to Triangle by Bukwang Pharm.
Ind., Co., Ltd. pursuant to a License Agreement dated February 27, 1998, as
amended on April 1, 1999 and on September 5, 2000 (the "L-FMAU License
Agreement"), for use as a pharmaceutical product in all human antiviral
applications and uses for the entire world, excluding Korea. Abbott's rights and
obligations under the L-FMAU License Agreement will terminate as a result of
termination of the Collaboration Agreement pursuant to Section 2.1 of this
Agreement.

     1.15 "MKC-442" shall mean the compound known as MKC-442, with the chemical
name 6-Benzyl-l-(ethoxy methyl)-5-isopropyl uracil, including any salts and
esters thereof. MKC-442 is exclusively licensed to Triangle by Mitsubishi
Chemical Corporation pursuant to a License Agreement dated June 17, 1997, as
amended January 1, 2001 and as terminated January 17, 2002 (the "MKC-442 License
Agreement"), for use as a pharmaceutical product in the entire world, excluding
Japan. Abbott's rights and obligations under the MKC-442 License Agreement will
terminate as a result of termination of the Collaboration Agreement pursuant to
Section 2.1 of this Agreement.

     1.16 "Manufacturing Agreement" shall have the meaning set forth in the
first "Whereas Clause."

     1.17 "Net Selling Price"

          (a)  "Net Selling Price" of Products which contain as their active
     ingredients only FTC (a "Sole Ingredient Product") shall mean the gross
     selling price paid by a purchaser in a Sale of such Sole Ingredient Product
     to Triangle, an Affiliate or sublicensee of Triangle, or any other party
     authorized by Triangle to sell Sole Ingredient Products plus, if
     applicable, the value of all properties and services received in
     consideration of a Sale of a Sole Ingredient Product, less only (i)
     discounts, rebates, sales, use, or other similar taxes, transportation and
     handling charges and allowances; and (ii) returns which are accepted by
     Triangle from independent customers in accordance with Triangle's normal
     practice and for which Triangle gives credit to such purchasers or
     retroactive price reductions in lieu of returns, whether during the
     specific royalty period or not. Where a Sale is deemed consummated by a
     gift, use, or other disposition of Sole

<Page>

                                      - 5 -

     Ingredient Products, for other than a selling price stated in cash, the
     term "Net Selling Price" shall mean the average gross selling price billed
     by Triangle in consideration of the cash Sales of comparable Sole
     Ingredient Products during the then current royalty period, less only
     reductions permitted in subsections (i) and (ii) above and such other
     reductions, if any, as the Triangle Licensor for FTC agrees are
     appropriate.

          (b)  "Net Selling Price" of Products which contain as their active
     ingredients both FTC and compounds other than FTC (a "Combination Product")
     shall be negotiated in good faith by the Parties with the intention of
     agreeing upon a fair and equitable formula; provided, however, that if the
     Parties are unable to agree upon such formula within a reasonable period of
     time, the Net Selling Price with respect to such Combination Product shall
     mean the gross sales price of such Combination Product billed to
     independent customers, less all the allowances, adjustments, reductions,
     discounts, taxes, duties, rebates or other charges referred to in Clause
     (a) multiplied by a fraction, the numerator of which shall be the average
     invoice price per gram of FTC contained in the most comparable stock
     keeping unit of any product having FTC as the sole active ingredient during
     the applicable royalty period in the applicable country, when such
     comparable product is sold for the same indication as such Combination
     Product and the denominator of which shall be the average invoice price per
     gram of FTC sold alone as described immediately above plus the average
     invoice price(s) per gram of the other active ingredient(s) contained in
     such Combination Product in such country during the applicable royalty
     period when such active ingredients are Sold alone for the same indication
     as such Combination Product. If there is no average invoice price per gram
     in a given country for one or more of the active ingredients comprising a
     Combination Product, the Net Selling Price with respect to such Combination
     Product shall be deemed to be the gross Sales of such Combination Product
     billed to independent customers, less all the allowances, adjustments,
     reductions, discounts, taxes, duties, rebates or other charges referred to
     in Clause (a), times a fraction, the numerator of which is one and the
     denominator of which is the number of all active ingredients in such
     Combination Product.

     1.18 "New Agreements" shall mean this Agreement and the following other
agreements being entered into by the Parties of even date herewith: (i) First
Amendment to Stockholder Rights Agreement; (ii) Manufacturing Agreement; and
(iii) Credit Agreement, and (iv) the Stockholder Rights Agreement, as amended by
the First Amendment thereto.

     1.19 "Parties" shall mean Triangle and Abbott.

     1.20 "Prior Agreements" shall mean the Collaboration Agreement, the Stock
Purchase Agreement, the Prior Manufacturing Agreement and the Co-Promotion
Agreement.

<Page>

                                      - 6 -

     1.21 "Product" shall mean any pharmaceutical product containing one or more
Compounds as active ingredients, alone or in combination with other active
ingredients, within their respective Field of Use.

     1.22 "Sold" or "Sale" shall mean the sale, transfer, exchange or other
disposition of Products whether by gift, or otherwise, subsequent to regulatory
approval in a given country (if regulatory approval is required) by Abbott or
its permitted sublicensees. Sales of Product shall be deemed consummated upon
the first to occur of: (a) receipt of payment from purchaser; (b) delivery of
Product to the purchaser or a common carrier; (c) release of Product from
consignment; or (d) if otherwise transferred, exchanged or disposed of by gift
or otherwise, when such transfer, exchange, gift or other disposition occurs.
Notwithstanding the foregoing definition of Sale, to the extent that Triangle
distributes any Product under a treatment IND or other expanded access program,
and such distribution is at a sales price which exceeds its fully absorbed costs
therefor, such amount shall be deemed part of the Net Selling Price. The
distribution of sample packs shall not be deemed a Sale.

     1.23 "Sole Ingredient Product" shall have the meaning set forth in Section
1.14.

     1.24 "Stockholder Rights Agreement" shall have the meaning set forth in the
first "Whereas Clause."

     1.25 "Triangle Licensors" shall mean Mitsubishi Chemical Corporation with
respect to MKC-442, Emory University with respect to FTC, Emory University and
the University of Georgia Research Foundation, Inc. with respect to DAPD, and
Bukwang Pharm. Ind., Co., Ltd. with respect to L-FMAU.

                                    ARTICLE 2

                       TERMINATION, RELEASE AND COVENANTS

     2.1  TERMINATION. Abbott and Triangle hereby terminate each of the Prior
Agreements as of the Effective Date. Notwithstanding any provisions contained in
any Prior Agreement to the contrary, none of the rights or obligations
thereunder will survive this termination.

     2.2  RELEASE.

          (a)  Each Party (the "Releasing Party"), for good and valuable
     consideration, the receipt and sufficiency of which is hereby acknowledged
     and intending to be legally bound, hereby releases and forever discharges
     the other Party and its past, present, and future employees, agents,
     representatives, Affiliates, stockholders, successors and assigns
     (individually, a "Releasee" and collectively, "Releasees") from any and all
     claims, demands, proceedings, causes of action, obligations, contracts,
     agreements, debts and liabilities whatsoever, whether known or unknown,
     suspected or unsuspected, both at law and in equity (collectively,
     "Claims") which the Releasing Party now has, has ever had, or may hereafter
     have against the respective Releasees

<Page>

                                      - 7 -

     arising out of any matter, cause, or event occurring prior to the Effective
     Date, including, but not limited to, any rights to indemnification or
     reimbursement, whether pursuant to any of the Prior Agreements, the
     Stockholder Rights Agreement or otherwise; provided, however, that this
     Release shall not release or discharge (i) any Claims by Releasing Party
     against the Releasees arising on or after the Effective Date under the New
     Agreements, (ii) the accrued payment obligations specified on Exhibit
     2.2(a) to this Agreement, which the Parties will pay within *** of the
     Effective Date, or (iii) an additional invoice from Abbott to Triangle in
     the amount of *** dollars ($***) for drug product expenses for July, 2002,
     which Triangle will pay within thirty (30) days after receipt and
     satisfactory review.

          (b)  The Releasing Party hereby irrevocably covenants to refrain from,
     directly or indirectly, asserting any claim or demand, or commencing,
     instituting, or causing to be commenced any proceeding of any kind, against
     any Releasee, based upon any Claim released hereby. The Releasing Party
     shall indemnify and hold harmless each Releasee from and against all loss,
     liability, claim, damage (including incidental and consequential damages)
     or expense (including costs of investigation and defense and reasonable
     attorney's fees) arising directly or indirectly from or in connection with
     the assertion by or on behalf of the Releasing Party of any Claim released
     hereby.

     2.3  RESIGNATION. Contemporaneously with execution of this Agreement,
Abbott will cause its representative on Triangle's Board of Directors to resign
and shall deliver his written resignation to Triangle.

                                    ARTICLE 3
                                     LICENSE

     Abbott hereby grants Triangle, with the right to grant sublicenses, a
perpetual, worldwide, non-exclusive, royalty-free (other than the royalty
obligation set forth in Article 4 of this Agreement) license to utilize Abbott
Technology and Abbott Patents to develop, make, have made, import, use, offer to
sell and sell the Compounds and Products within the Field of Use. The right to
grant sublicenses is limited, however, with respect to any Abbott Technology or
Abbott Patents licensed by Abbott from a third party that is unwilling to
provide its consent to such sublicense despite Abbott's reasonable best efforts
to procure such consent. The Parties will reasonably cooperate in the
enforcement of any Abbott Patents.

                                    ARTICLE 4
                               ROYALTY AND REPORTS

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                      - 8 -

     4.1  ROYALTY. Triangle shall pay a one percent royalty on the Net Selling
Price of Products which contain FTC as an active ingredient. Such royalty shall
apply only until Abbott has been paid an aggregate of Two Million Dollars
(US$2,000,000) in royalties by Triangle. In lieu of paying such amount in
royalties and in full satisfaction of its obligations under this Section 4.1,
Triangle may, at any time and in its sole discretion, prepay Abbott Two Million
Dollars (US$2,000,000) (less any royalties that have already been paid to Abbott
under this Section 4.1).

     4.2  ROYALTY REPORTS AND RECORDS. Until payment of the full amounts
required to be paid pursuant to Section 4.1, Triangle shall furnish, or cause to
be furnished to Abbott, written reports covering each of Triangle's, Triangle's
Affiliates' and Triangle's sublicensees' fiscal quarters showing:

          (a)  the gross selling price of all Sole Ingredient Products and
     Combination Products Sold by Triangle, its Affiliates and sublicensees, in
     each country during the reporting period;

          (b)  the royalties payable in Dollars, which shall have accrued
     hereunder in respect to such Sales;

          (c)  the exchange rates used, if any, in determining the amount of
     Dollars, which exchange rates shall be the same used in its report of Sales
     to the Triangle Licensor of FTC; and

          (d)  a summary of the calculation of any payments due Abbott pursuant
     to Section 4.1 of this Agreement.

Reports shall be made quarterly after the first Sale of a Product containing FTC
as an active ingredient. Quarterly reports shall be due within sixty (60) days
of the close of every Triangle fiscal quarter until payment of the full amounts
required to be paid pursuant to Section 4.1. Triangle shall keep accurate
records in sufficient detail to enable royalties and other payments payable
hereunder to be determined.

     4.3  AUDIT. Until payment of the full amount of royalties required pursuant
to Section 4.1 Abbott shall have the right, upon prior notice to Triangle, not
more than once in each Triangle fiscal year nor more than once in respect of any
fiscal year, through an independent certified public accountant selected by
Abbott and acceptable to Triangle, which acceptance shall not be unreasonably
refused, to have access during normal business hours to those records of
Triangle as may be reasonably necessary to verify the accuracy of the royalty
reports required to be furnished by Triangle pursuant to Section 4.2 of this
Agreement. Triangle shall obtain and maintain appropriate records of Sales made
pursuant to any sublicenses granted pursuant to the FTC License Agreement. If
such independent certified public accountant's report shows any underpayment of
royalties by Triangle, its Affiliates or sublicensees, within thirty (30) days
after Triangle's receipt of such report, Triangle shall remit to Abbott:

          (a)  the amount of such underpayment; and

<Page>

                                      - 9 -

          (b)  if such underpayment exceeds *** percent (***%) of the total
     royalties owed for the fiscal year then being reviewed, the reasonably
     necessary fees and expenses of such independent certified public accountant
     performing the audit. Otherwise, Abbott's accountant's fees and expenses
     shall be borne by Abbott. Upon the expiration of *** following the end of
     any fiscal year, the calculation of royalties payable with respect to such
     fiscal year shall be binding and conclusive on Abbott and Triangle, unless
     an audit is initiated before the expiration of such ***.

     4.4  CONFIDENTIALITY OF RECORDS. All information subject to review under
this Article 4 shall be deemed Confidential Information of Triangle under
Article 8.

                                    ARTICLE 5

                               TRANSITION SERVICES

     5.1  SERVICES. Abbott shall provide the following transitional services to
Triangle by performing the Transitional Services Plan described below:

          (a)  transfer of the Abbott Technology to Triangle and assistance in
     understanding, utilizing and, if possible and desirable, securing patent
     protection therefor;

          (b)  provide support, documentation and assistance for the completion
     of the registration process in the United States and Europe for FTC as the
     FTC supplier, including Chemistry and Manufacturing Control sections of the
     U.S. New Drug Application and the European filing for FTC and the transfer
     of responsibility for the European applications to Triangle (the
     "Registration Transition Services").

     5.2  TRANSITION PLANS.

          (a)  With respect to FTC, the transfer of Abbott Technology to
     Triangle referred to in Section 5.1(a) above is occurring pursuant to the
     transition services arrangements in the Manufacturing Agreement. Abbott's
     completion of its transfer obligations set forth in the Manufacturing
     Agreement will satisfy its transfer obligations set forth in Section 5.1(a)
     above.

          (b)  Attached as Exhibit 5.2 is the Transitional Services Plan that
     governs the Registration Transition Services to be provided by Abbott, the
     schedule for completing each part of such transition and an estimated
     budget for the Registration Transition Services. Abbott shall not be
     required to provide any services with respect to Registration Transition
     Services except as specified in the Transitional Services Plan or as
     otherwise agreed upon by the Parties in writing.

     5.3  COST. The cost of the transitional services set forth in Section
5.1(a) above shall be governed by the Manufacturing Agreement. With respect to
the Registration Transition Services,

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                     - 10 -

Triangle shall pay Abbott for all reasonable internal costs and reasonable
out-of-pocket expenses incurred by Abbott in connection therewith; provided that
such internal costs and out-of-pocket expenses shall not exceed the
corresponding agreed to budget for such services set forth in the Transitional
Service Plan. Abbott shall invoice Triangle on a monthly basis for services
rendered in the prior month, and such invoices shall be paid in full by Triangle
within thirty (30) days after receipt of Abbott's invoice. Triangle shall bear
its own costs and expenses and pay all third party costs and expenses incurred
pursuant to the Transitional Services Plan. Triangle shall contract directly
with such third parties for their support and assistance, and Abbott shall not
commit or enter into any contracts with any such third parties for transitional
services on Triangle's behalf.

                                    ARTICLE 6
                         REPRESENTATIONS AND WARRANTIES

     6.1  ABBOTT REPRESENTATIONS AND WARRANTIES. Abbott hereby represents and
warrants to Triangle as follows:

          (a)  Abbott has the right to grant Triangle the license granted in
     Article 3 of this Agreement;

          (b)  to Abbott's knowledge:

               (i)   as of the Effective Date, there are no Abbott Patents;

               (ii)  as of the Effective Date, there is no Abbott Technology
          concerning any Compound other than FTC;

               (iii) all Abbott Technology is owned by Abbott, and none is
          licensed by Abbott from a third party;

               (iii) Triangle's exercise of the Abbott Patents and the Abbott
          Technology in the manner exercised by Abbott as of the Effective Date
          will not infringe the intellectual property or any other rights of any
          third party;

               (iv)  Abbott has not received any notice from any third party
          asserting that the exercise of the Abbott Patents or the Abbott
          Technology infringes the intellectual property or other rights of any
          third party;

               (v)   except for intellectual property rights of a Third Party
          supplier with respect to raw materials supplied by such supplier, no
          intellectual property rights of any third party, including Abbott's
          raw material suppliers and TAP, other than the Abbott Patents and
          Abbott Technology and the Triangle Patents and Triangle Technology
          (each as defined in the Manufacturing Agreement), are necessary for
          the manufacture of the Products as each is manufactured as of the
          Effective Date by Abbott.

<Page>

                                     - 11 -

          (c)  Abbott is a corporation duly organized and validly existing in
     good standing under the laws of its state of incorporation, with all
     requisite corporate power and authority to own, lease and operate its
     properties and assets and to carry on its business as presently conducted
     and as proposed to be conducted;

          (d)  Abbott has all requisite corporate right, power and authority to
     enter into this Agreement and the other New Agreements and to consummate
     the transactions contemplated hereby and thereby. The execution and
     delivery of this Agreement and the other New Agreements by Abbott and the
     consummation by Abbott of the transactions contemplated hereby and thereby
     have been duly authorized by all necessary corporate action on Abbott's
     behalf;

          (e)  the execution, delivery and performance by Abbott of this
     Agreement and each of the other New Agreements and Abbott's compliance with
     the terms and provisions hereof and thereof will not result in any
     violation of, or default under (with or without notice or lapse of time, or
     both), or give rise to a right of termination, cancellation or acceleration
     of any obligation pursuant to, or a loss of benefits under, any provision
     of Abbott's Articles of Incorporation or By-Laws, or any mortgage,
     indenture, lease or other agreement or instrument, license, judgment,
     order, decree, statute, law, ordinance, rule or regulation applicable to
     Abbott, its properties or assets; and

          (f)  no consent, approval or authorization of, or designation,
     declaration or filing with any governmental authority is required in
     connection with the valid execution, delivery or performance of this
     Agreement and the other New Agreements by Abbott or the consummation by
     Abbott of the transactions contemplated hereby or thereby, except such
     filings as may be required to be made with the Securities and Exchange
     Commission or any national securities exchange or market. Upon their
     execution and delivery, and assuming the valid execution thereof by
     Triangle, this Agreement and the other New Agreements will constitute valid
     and binding obligations of Abbott, enforceable in accordance with their
     respective terms, except as enforceability may be limited by applicable
     bankruptcy, insolvency, reorganization, moratorium or similar laws
     affecting creditors' and contracting parties' rights generally and except
     as enforceability may be subject to general principles of equity
     (regardless of whether such enforceability is considered in a proceeding in
     equity or at law).

     6.2  TRIANGLE REPRESENTATIONS AND WARRANTIES. Triangle hereby represents
and warrants to Abbott as follows:

          (a)  Triangle is a corporation duly organized and validly existing in
     good standing under the laws of its state of incorporation, with all
     requisite corporate power and authority to

<Page>

                                     - 12 -

     own, lease and operate its properties and assets and to carry on its
     business as presently conducted and as proposed to be conducted;

          (b)  Triangle has all requisite corporate right, power and authority
     to enter into this Agreement and the other New Agreements and to consummate
     the transactions contemplated hereby and thereby. The execution and
     delivery of this Agreement and the other New Agreements by Triangle and the
     consummation by Triangle of the transactions contemplated hereby and
     thereby have been duly authorized by all necessary corporate action on
     Triangle's behalf;

          (c)  the execution, delivery and performance by Triangle of this
     Agreement and each of the other New Agreements and Triangle's compliance
     with the terms and provisions hereof and thereof will not result in any
     violation of, or default under (with or without notice or lapse of time, or
     both), or give rise to a right of termination, cancellation or acceleration
     of any obligation pursuant to, or a loss of benefits under, any provision
     of its Certificate of Incorporation or By-Laws, or any mortgage, indenture,
     lease or other agreement or instrument, license, judgment, order, decree,
     statute, law, ordinance, rule or regulation applicable to Triangle, or
     Triangle's properties or assets;

          (d)  no consent, approval or authorization of, or designation,
     declaration or filing with any governmental authority is required in
     connection with the valid execution, delivery or performance of this
     Agreement and the other New Agreements by Triangle or the consummation by
     Triangle of the transactions contemplated hereby or thereby, except such
     filings as may be required to be made with the Securities and Exchange
     Commission or any national securities exchange or market. Upon their
     execution and delivery, and assuming the valid execution thereof by Abbott,
     this Agreement and the other New Agreements will constitute valid and
     binding obligations of Triangle, enforceable in accordance with their
     respective terms, except as enforceability may be limited by applicable
     bankruptcy, insolvency, reorganization, moratorium or similar laws
     affecting creditors' and contracting parties' rights generally and except
     as enforceability may be subject to general principles of equity
     (regardless of whether such enforceability is considered in a proceeding in
     equity or at law); or

          (e)  James L. Tyree, Abbott's representative on the Triangle Board of
     Directors, has received all material information regarding the clinical
     development and registration of FTC which has been provided to all of
     Triangle's other outside directors.

     6.3  NO OTHER WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, EACH PARTY MAKES NO OTHER WARRANTIES OR REPRESENTATIONS,

<Page>

                                     - 13 -

INCLUDING FITNESS FOR PURPOSE INTENDED OR MERCHANTABILITY, WHETHER EXPRESS OR
IMPLIED.

                                    ARTICLE 7
                             LIMITATION ON LIABILITY

     EXCEPT AS OTHERWISE PROVIDED, NEITHER PARTY SHALL BE LIABLE FOR ANY
SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL LOSSES ARISING OUT OF OR RELATING
TO THIS AGREEMENT.

                                    ARTICLE 8
                        CONFIDENTIALITY AND NONDISCLOSURE

     8.1  CONFIDENTIALITY OBLIGATION. Except as permitted below, each of Abbott
and Triangle (the "Receiving Party") shall keep strictly confidential any
information disclosed in writing, orally, visually or in any other manner by the
other Party (the "Disclosing Party") or otherwise made available to the
Receiving Party which the Disclosing Party considers to be and treats as
proprietary and confidential ("Confidential Information"). Without limiting the
generality of the foregoing, all proprietary information concerning the
Disclosing Party's business operations, suppliers, products, product
manufacture, sale, marketing or distribution, trade secrets and intellectual
property shall be considered Confidential Information by the Receiving Party.
Any data or other information relating to or resulting from the clinical trials
of the Products shall be deemed to be Confidential Information of Triangle. The
Disclosing Party shall use commercially reasonable efforts to designate any
written Confidential Information disclosed to the other Party as Confidential
Information by prominently marking it "confidential", "proprietary" or the like,
provided, that the failure to so mark shall not exclude such written information
from the provisions of this Section 8. "Confidential Information" shall not
include information:

          (a)  which is or becomes generally available to the public other than
     as a result of disclosure thereof by the Receiving Party;

          (b)  which is lawfully received by the Receiving Party on a
     non-confidential basis from a third party that is not itself under any
     obligation of confidentiality or nondisclosure to the Disclosing Party or
     any other person with respect to such information;

          (c)  which by written evidence can be shown by the Receiving Party to
     have been independently developed by or for the Receiving Party; or

          (d)  which the Receiving Party establishes by competent proof was in
     its possession at the time of disclosure by the other Party and was not
     acquired, directly or indirectly from the other Party.

<Page>

                                     - 14 -

All information, data and other materials constituting protected information
under or otherwise disclosed by one Party to the other pursuant to any of the
Prior Agreements shall be deemed to have been disclosed by the Disclosing Party
under this Agreement.

     8.2  NONDISCLOSURE OF CONFIDENTIAL INFORMATION. The Receiving Party shall
use Confidential Information solely for the purposes of the New Agreements and
shall not disclose or disseminate any Confidential Information to any third
party at any time without the Disclosing Party's prior written consent, except
for disclosure to those of its directors, officers, employees, accountants,
attorneys, advisers, and agents whose duties reasonably require them to have
access to such Confidential Information and, in the case of Triangle, disclosure
to the Triangle Licensors and to sublicensees and actual or potential business
partners (including any Third Party with which Triangle collaborates in the
development, registration, manufacture, use or sale of the Compounds or
Products), provided that such directors, officers, employees, accountants,
attorneys, advisers, sublicensees, agents and Triangle Licensors and business
partners are required to use the Confidential Information solely for purposes of
the New Agreements and maintain the confidentiality of such Confidential
Information to the same extent as if they were parties hereto.

     8.3  EXCEPTION. The foregoing confidentiality and nondisclosure obligations
shall not apply to information which is required to be disclosed by law or by
regulation; provided, that (i) the Receiving Party gives the Disclosing Party
reasonable advance notice of the disclosure, to the extent reasonably
practicable and legally permissible; (ii) the Receiving Party uses reasonable
efforts to resist and limit disclosing the Confidential Information; (iii) the
Receiving Party reasonably cooperates with the Disclosing Party on request to
obtain a protective order or otherwise limit the disclosure; and (iv) upon the
reasonable request of the Disclosing Party, the Receiving Party shall provide a
letter from its counsel confirming that the Confidential Information is, in
fact, required to be disclosed.

     8.4  INJUNCTIVE RELIEF. The Parties acknowledge that either Party's breach
of this Article 8 may cause the other Party irreparable injury for which it
would not have an adequate remedy at law. In the event of a breach, the
non-breaching Party shall be entitled to seek injunctive relief in addition to
any other remedies it may have at law or in equity.

     8.5  SCIENTIFIC AND OTHER PUBLICATIONS Notwithstanding anything herein to
the contrary, it is the understanding of each Party that scientific, scholarly
and other related publications or presentations concerning the development of
the Compounds and the Products, including their pre-clinical and clinical
development, shall emanate solely from Triangle and the trials and studies
sponsored by Triangle and that, as against Abbott, Triangle shall have full
control over the preparation, review and approval of such publications and
presentations, which publications and presentations shall not be restricted
hereunder.

<Page>

                                     - 15 -

     8.6  CONFIDENTIALITY PERIOD. The confidentiality and non-disclosure
obligations of this Article 8 shall remain in effect for a period of *** years
from the Effective Date.

                                    ARTICLE 9

                                  FORCE MAJEURE

     If any circumstance beyond the reasonable control of either Party occurs
which delays or renders impossible the performance of certain of that Party's
obligations under this Agreement on the dates herein provided (a "Force
Majeure"), such obligations shall be postponed for such time as such performance
necessarily has had to be suspended or delayed on account thereof, provided such
Party shall notify the other Party in writing as soon as practicable, but in no
event more than ten (10) business days after the occurrence of such event of
Force Majeure, which notice shall reasonably attempt to identify such
obligations under this Agreement and the extent to which performance thereof
will be affected. In such event, the Parties shall meet promptly to determine an
equitable solution to the effects of any such event, provided that such Party
who fails because of an event of Force Majeure to perform its obligations
hereunder shall upon the cessation of the Force Majeure event take all
reasonable steps within its power to resume with the least possible delay
compliance with its obligations. Events of Force Majeure shall include, without
limitation, war, revolution, invasion, insurrection, terrorism, riots, mob
violence, sabotage or other civil disorders, acts of God, limitations imposed by
exchange control regulations or foreign investment regulations or similar
regulations, laws, regulations or rules of any government or governmental
agency, any delay or failure in manufacture, production or supply by third
parties of any goods or services, and any withdrawal or recall of a Product at
the direction of any governmental authority.

                                   ARTICLE 10
                                  MISCELLANEOUS

     10.1 RELATIONSHIP OF THE PARTIES. Each of the Parties shall be furnishing
its services hereunder as an independent contractor, and nothing herein shall
create any association, partnership or joint venture between the Parties or any
employer-employee relationship. No agent, employee or servant of either Party
shall be or shall be deemed to be the employee, agent or servant of the other
Party, and each Party shall be solely and entirely responsible for its acts and
the acts of its employees.

     10.2 RELATIONSHIP WITH AFFILIATES. Unless the context otherwise indicates,
(i) any reference to a Party herein shall include the Affiliates of such Party
(by whom such Party will ensure compliance herewith) and (ii) each Party may
utilize the services of its Affiliates to perform services, activities and/or
obligations permitted or required under this Agreement to the same extent as if
such Affiliate were a party

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                     - 16 -

to this Agreement. Any Affiliates so utilized shall be subject to all the terms
and conditions applicable to such Party under this Agreement, including but not
limited to provisions establishing standards for performance. The use of any
Affiliates as set forth in this Section 10.2 shall in no way relieve the
applicable Party of any of its obligations or liabilities hereunder and each
Party shall be liable for the actions of its Affiliates under this Agreement.

     10.3 DISPUTE RESOLUTION.

          (a)  GENERAL. The Parties recognize that a bona fide dispute as to
     certain matters may arise from time to time during the term of this
     Agreement which may relate to either Party's rights and/or obligations
     hereunder. The Parties agree that they shall use all reasonable efforts to
     resolve any dispute which may arise in an amicable manner.

          (b)  MANAGEMENT RESOLUTION. Either Party may, by notice to the other
     Party, refer any dispute hereunder to the respective officers of the
     Parties designated below. Such officers shall attempt to resolve the
     referred dispute by good faith negotiations within *** after such notice is
     received. The said designated officers are as follows: For Abbott, the Vice
     President, Global Licensing/New Business Development and for Triangle, the
     Chief Operating Officer.

          (c)  ALTERNATIVE DISPUTE RESOLUTION. The Parties agree that any
     dispute that arises under this Agreement, which cannot be amicably resolved
     by such management discussions shall be resolved by binding Alternative
     Dispute Resolution ("ADR") in the manner described in Exhibit 10.3.

          (d)  LIMITED INJUNCTIVE RELIEF PERMITTED. Notwithstanding the
     foregoing, nothing shall limit the Parties' right to seek judicial
     injunctive relief pursuant to Section 8.4 with respect to a breach or
     threatened breach of the requirements set forth in Article 8 hereof.

     10.4 COUNTERPARTS. The Agreement may be executed simultaneously in any
number of counterparts and may be executed by facsimile. All counterparts shall
collectively constitute one and the same Agreement.

     10.5 NOTICES. In any case where any notice or other communication is
required or permitted to be given hereunder, such notice or communication shall
be in writing, and sent by overnight express or registered or certified mail
(with return receipt requested) and shall be sent to the following address (or
such other address as either Party may designate from time to time in writing):

          If to Triangle:
                   Triangle Pharmaceuticals, Inc.
                   4 University Place
                   4611 University Drive

----------
*** Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.

<Page>

                                     - 17 -

                   Durham, North Carolina 27707
                   Telephone:  (919) 493-5980
                   Telefax:    (919) 493-5925
                   Attention:  Chief Operating Officer
                   Copy to:    General Counsel

          Copy to:
                   Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
                   2500 First Union Capitol Center
                   Raleigh, North Carolina 27601
                   Telephone:  (919) 821-1200
                   Telefax:    (919) 821-6800
                   Attention:  Gerald F. Roach

          If to Abbott:
                   Abbott Laboratories
                   Dept.  R50A; Bldg.  AP34
                   200 Abbott Park Road
                   Abbott Park, IL 60064-6187
                   Telephone:  (847) 938-0101
                   Telefax:    (847) 937-1771
                   Attention:  Vice President, Global Licensing/New Business
                               Development

          Copy to:
                   General Counsel
                   Abbott Laboratories
                   Dept.  364; Bldg.  AP6D
                   100 Abbott Park Road
                   Abbott Park, IL 60064-6020
                   Telephone:  (847) 937-8906
                   Telefax:    (847) 938-6277

     10.6 BINDING EFFECT; ASSIGNMENT. This Agreement may not be assigned, in
whole or in part, by either Party without the prior written consent of the other
Party, and any attempted assignment without such consent shall be null and void;
provided that no prior written consent shall be required in the event that a
third party acquires substantially all of the assets or outstanding shares of,
or merges with, the assigning Party, but only so long as such third party agrees
to be bound by all of the assigning Party's responsibilities and obligations
hereunder; and provided further that no prior written consent shall be required
from Abbott with respect to any sublicense by Triangle of its rights under
Article III to any third party, other than any consents required under the
corresponding primary licenses to Abbott. No assignment of this Agreement or of
any rights hereunder shall relieve the assigning Party of any of its obligations
or liability hereunder. This Agreement shall inure to the benefit of and be
binding upon each of the Parties hereto and their respective successors and
permitted assigns.

     10.7 ENTIRE AGREEMENT. The terms and conditions contained herein and in the
other New Agreements constitute the entire agreement between the Parties
relating to the subject matter hereof and

<Page>

                                     - 18 -

thereof and shall supersede all of the Prior Agreements and all previous
communications between the Parties with respect to the subject matter hereof and
thereof, respectively. Neither Party has entered into this Agreement in reliance
upon any representation, warranty, covenant or undertaking of the other Party
that is not set out or referred to in this Agreement.

     10.8 AMENDMENT. The Agreement may be varied, amended or extended only by
the written agreement of the Parties through their duly authorized officers or
representatives, specifically referring to this Agreement.

     10.9 SEVERABILITY. In case any one or more of the provisions contained
herein shall, for any reason be held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability shall not affect
any other provision of this Agreement, but this Agreement shall be construed as
if such invalid, illegal or unenforceable provision or provisions had never been
contained herein unless the deletion of such provision or provisions would
result in such a material change as to cause completion of the transactions
contemplated herein to be impossible and provided that the performance required
by this Agreement with such clause deleted remains substantially consistent with
the intent of the Parties.

     10.10 COMPANY EMPLOYEES. For a period of one (1) year from the Effective
Date, each Party shall not, directly or indirectly solicit for employment, any
employee of the other Party who has been directly involved in the performance of
the Prior Agreements, or the New Agreements. It shall not be a violation of this
provision if any employee responds to a Party's general advertisement of an open
position.

     10.11 PUBLICITY. Except as otherwise provided herein, each Party shall
maintain the confidentiality of all provisions of this Agreement and this
Agreement itself and, without the prior written consent of both Parties, neither
Party shall make any press release or other public announcement of or otherwise
disclose to any third party this Agreement or any of its provisions except: (i)
for disclosure to those of its directors, officers, employees, accountants,
attorneys, advisers, sublicensees and agents whose duties reasonably require
them to have access to the Agreement and, in the case of Triangle, disclosure to
the Triangle Licensors and to sublicensees and actual and potential business
partners (including any Third Party with which Triangle collaborates in the
development, registration, manufacture, use or sale of the Compounds or
Products), provided that such directors, officers, employees, accountants,
attorneys, advisers, agents, licensors, sublicensees and business partners are
required to maintain the confidentiality of the Agreement to the same extent as
if they were parties hereto, and (ii) except for such disclosures as may be
required by legal requirements, in which case the disclosing Party shall provide
the nondisclosing Party with prompt advance notice of such disclosure so that
the nondisclosing Party shall have the opportunity if it so desires to seek a
protective order or other appropriate remedy and, in connection with

<Page>

                                     - 19 -

any disclosure to the Securities and Exchange Commission, the disclosing Party
shall use reasonable efforts (at the nondisclosing Party's written request) to
obtain confidential treatment for such disclosure. Promptly following the
execution of this Agreement, Triangle will issue a press release, a copy of
which is attached hereto as Exhibit 10.11.

     10.12 APPLICABLE LAW. The Agreement shall be governed by the laws of the
State of Delaware applicable to contracts made and to be performed entirely
within such jurisdiction and without giving effect to its choice or conflict of
laws rules or principles. If any action at law or in equity is necessary to
enforce or interpret the terms of this Agreement, the prevailing Party shall be
entitled to reasonable attorneys' fees, costs and necessary disbursements, in
addition to any other relief to which the Party may be entitled.

     10.13 HEADINGS. The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect the meaning or
interpretation of this Agreement.

     10.14 INTERPRETATION.

          (a)  Wherever any provision of this Agreement uses the term
     "including" (or "includes"), such term shall be deemed to mean "including
     without limitation" and "including but not limited to" (or "includes
     without limitation" and "includes but is not limited to") regardless of
     whether the words "without limitation" or "but not limited to" actually
     follow the term "including" (or "includes").

          (b)  Wherever any provision of this Agreement provides that a Party's
     consent shall not be unreasonably withheld, such provision shall be deemed
     to provide that such consent shall in addition not be unreasonably delayed.

          (c)  The recitals set forth at the start of this Agreement, along with
     the Exhibits to this Agreement, and the terms and conditions incorporated
     in such recitals and Exhibits shall be deemed integral parts of this
     Agreement and all references in this Agreement to this Agreement shall
     encompass such recitals and Exhibits and the terms and conditions
     incorporated in such recitals and Exhibits.

          (d)  In the event of any conflict between the terms and conditions of
     this Agreement and any terms and conditions that may be set forth on any
     order, invoice, verbal agreement or otherwise, the terms and conditions of
     this Agreement shall govern.

          (e)  Unless otherwise explicitly stated, in the event of any conflict
     between the terms of this Agreement and the terms and conditions of any of
     the Exhibits hereto, the terms of this Agreement shall prevail.

          (f)  The Agreement shall be construed as if both Parties drafted it
     jointly, and shall not be construed against either Party as principal
     drafter.

<Page>

                                     - 20 -

          (g)  Unless otherwise provided, all references to Sections, Articles
     and Exhibits in this Agreement are to Sections, Articles and Exhibits of
     and to this Agreement.

     10.15 NO WAIVER OF RIGHTS. No failure or delay on the part of either Party
in the exercise of any power or right hereunder shall operate as a waiver
thereof. No single or partial exercise of any right or power hereunder shall
operate as a waiver of such right or of any other right or power. The waiver by
either Party of a breach of any provision of this Agreement shall not operate or
be construed as a waiver of any other or subsequent breach hereunder.

                                    *  *  *  *

<Page>

                    [SIGNATURE PAGE TO TERMINATION AGREEMENT]

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized officers as of the date first written above.

ABBOTT LABORATORIES                             TRIANGLE PHARMACEUTICALS, INC.

By:     /s/ Jeffrey M. Leiden, MD, Ph.D         By:     /s/ Chris A. Rallis
        -------------------------------------           ------------------------

Name:   Jeffrey M. Leiden, MD, Ph.D             Name:   Chris A. Rallis
        -------------------------------------           ------------------------

Title:  President and Chief Operating Officer,  Title:  President and Chief
        Pharmaceutical Products Group                   Operating Officer
        -------------------------------------           ------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]